Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 21:14:1080117.
doi: 10.3389/fphar.2023.1080117. eCollection 2023.

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses

Ping Siu Kee  1 , Simran D S Maggo  1   2 , Martin A Kennedy  1 , Paul K L Chin  3   4
Affiliations

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses

Ping Siu Kee et al. Front Pharmacol. .

Abstract

Pharmacogenetics has potential for optimizing use of psychotropics. CYP2D6 and CYP2C19 are two clinically relevant pharmacogenes in the prescribing of antidepressants. Using cases recruited from the Understanding Drug Reactions Using Genomic Sequencing (UDRUGS) study, we aimed to evaluate the clinical utility of genotyping CYP2D6 and CYP2C19 in antidepressant response. Genomic and clinical data for patients who were prescribed antidepressants for mental health disorders, and experienced adverse reactions (ADRs) or ineffectiveness, were extracted for analysis. Genotype-inferred phenotyping of CYP2D6 and CYP2C19 was carried out as per Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A total of 52 patients, predominantly New Zealand Europeans (85%) with a median age (range) of 36 years (15-73), were eligible for analysis. Thirty-one (60%) reported ADRs, 11 (21%) ineffectiveness, and 10 (19%) reported both. There were 19 CYP2C19 NMs, 15 IMs, 16 RMs, one PM and one UM. For CYP2D6, there were 22 NMs, 22 IMs, four PMs, three UMs, and one indeterminate. CPIC assigned a level to each gene-drug pair based on curated genotype-to-phenotype evidence. We analyzed a subgroup of 45 cases, inclusive of response type (ADRs/ineffectiveness). Seventy-nine (N = 37 for CYP2D6, N = 42 for CYP2C19) gene-drug/antidepressant-response pairs with CPIC evidence levels of A, A/B, or B were identified. Pairs were assigned as 'actionable' if the CYP phenotypes potentially contributed to the observed response. We observed actionability in 41% (15/37) of CYP2D6-antidepressant-response pairs and 36% (15/42) of CYP2C19-antidepressant-response pairs. In this cohort, CYP2D6 and CYP2C19 genotypes were actionable for a total of 38% pairs, consisting of 48% in relation to ADRs and 21% in relation to drug ineffectiveness.

Keywords: Adverse drug reaction; CYP2C19; CYP2D6; Psychiatry; antidepressant; clinical utility; drug response; pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AG declared a shared consortium, with the author MK to the handling Editor.

References

    1. Arnone D., Omar O., Arora T., Ostlundh L., Ramaraj R., Javaid S., et al. (2023). Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. Neurosci. Biobehav. Rev. 144, 104965. 10.1016/j.neubiorev.2022.104965 - DOI - PubMed
    1. Bahramali E., Firouzabadi N., Yavarian I., Shayesteh M. R., Erfani N., Shoushtari A. A., et al. (2016). Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: A randomized controlled trial. Eur. J. Clin. Pharmacol. 72 (9), 1059–1064. 10.1007/s00228-016-2079-0 - DOI - PubMed
    1. Balant-Gorgia A. E., Gex-Fabry M., Balant L. P. (1991). Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. 20 (6), 447–462. 10.2165/00003088-199120060-00002 - DOI - PubMed
    1. Berg K. A., Clarke W. P. (2018). Making sense of pharmacology: Inverse agonism and functional selectivity. Int. J. Neuropsychopharmacol. 21 (10), 962–977. 10.1093/ijnp/pyy071 - DOI - PMC - PubMed
    1. Bousman C. A., Arandjelovic K., Mancuso S. G., Eyre H. A., Dunlop B. W. (2019). Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. Pharmacogenomics 20 (1), 37–47. 10.2217/pgs-2018-0142 - DOI - PubMed

LinkOut - more resources